Navigation Links
BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
Date:8/22/2008

ruses and spores. The Ygiene(TM) and Ogiene(TM) formulations are "Green" and include natural and common ingredients which are found in baby products and the foods we eat. These widely used compounds are combined in unique ways to create enhanced results.

BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. The products include BioNeutralizers and ChemoNeutralizers. BioNeutralizers disinfect, decontaminate and sterilize. BioNeutral believes it has the broadest-based, fastest acting, most effective and safest antimicrobial known. This class of products has important applications for consumers, healthcare and the military. ChemoNeutralizers irreversibly bind chemical contaminant and toxin molecules and render them harmless. Product applications include industrial pollution and protection against chemical weapons of mass destruction.

Contact Information:

BioNeutral Laboratories Corporation USA

http://www.bioneutrallabs.com

http://www.bioneutralgroup.com

Info@bioneutralgroup.com

Dr. Andy Kielbania

Chief Scientist

andy@bioneutralgroup.com

Stephen J. Browand

Director

Governmental Affairs

steve@bioneutralgroup.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
2. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
3. BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development
6. Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
7. Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract
8. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... This year has been one of the ... Patented Pearl’s Premium Ultra Low Maintenance Lawn Seed comes ... are coming out of record bad weather. Offering ... global concerns related to water, health, and climate change, ... to the standard, water-wasting, chemical-treated standard lawn. Many ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... , GAITHERSBURG, Md., Aug. 6 GenVec, Inc. (Nasdaq: ... quarter ended June 30, 2009. , , ... GenVec reported a net loss of $4.8 million ($0.05 per ... net loss of $6.6 million ($0.08 per share) in the comparable quarter ...
... , ROCKVILLE, Md., Aug. 6 Novavax, Inc. ... Frederick W. Driscoll as Vice President, Chief Financial Officer and ... Novavax,s President and Chief Executive Officer. , , ... President and Chief Executive Officer of Genelabs Technologies, Inc. ...
... , NEWTON, Mass., Aug. 6 Microfluidics International ... release second quarter 2009 financial results on Tuesday, August 11, ... , Michael C. Ferrara, President and Chief Executive Officer, ... Officer, will host a conference call and live audio webcast at ...
Cached Biology Technology:GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
... Harbor, N.Y. Much like cancer cells, plant cells ... milieu, in culture dishes, have highly unstable genomes. Changes ... cells cope with challenging culture conditions but inadvertently also ... of DNA that can jump around in the genome, ...
... can have genetic causes. Researchers at the Institute of ... correlation. The causes of what is known as irritable ... of the gastrointestinal tract, are considered unclear making ... which were published in the prestigious jour-nal " Human ...
Cached Biology News:UQ research targets West Nile virus and dengue fever 2CSHL researchers map changing epigenetic modifications that enable transposons to run amok 2Irritable bowel syndrome can have genetic causes 2
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
Biology Products: